Akron Biotechnology, LLC
1095 Broken Sound Pkwy. NW
16 articles with Akron Biotechnology, LLC
Akron Biotechnology, which develops and manufactures cGMP-compliant cytokines and other ancillary materials to enable cell and gene therapy development and commercialization, today announced that it has submitted Type II Drug Master Files (DMF
The following is a roundup of some of this week's non-coronavirus biopharma news.
New Site in Sarasota, FL, Increases Akron’s US Manufacturing Capacity for Cell and Gene Therapy Materials and Technologies
Paper published in "Cytotherapy" to propose framework for critical standardization of ATMP material regulation
Arcline Investment Management Acquires Majority Interest In Cell And Gene Therapy Materials Supplier Akron Biotechnology
Arcline Investment Management announced that it has acquired a majority interest in Akron Biotechnology LLC.
Akron Biotechnology, a leading supplier of ancillary materials to the regenerative medicine industry, announces that it has filed a Drug Master File (DMF) Type II for its Interleukin-2 (IL-2) in Electronic Common Technical Document (eCTD) format with the U.S. Food and Drug Administration (FDA).
Akron Biotechnology, LLC Awarded SBIR Grant For Development Of Novel Method To Isolate Adipose Derived Stem Cells
Akron Biotechnology, LLC Announces the Launch of: CryoSolve – A Single-Use cGMP Cell Cryopreservation Media